Tissue Chain of Custody Documentation | HCT/P Traceability Under 21 CFR Part 1271

Tissue Chain of Custody Documentation Under 21 CFR Part 1271

What is tissue chain of custody?
Tissue chain of custody refers to the documented process used to trace Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) from donor recovery through processing, storage, distribution, and final disposition.

In simple terms, chain-of-custody documentation helps maintain traceability and accountability throughout the handling of human tissue products.

Traceability and documentation are essential components of regulatory oversight for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). The regulatory framework established under 21 CFR Part 1271 includes requirements intended to support traceability throughout the lifecycle of eligible HCT/Ps.

Chain-of-custody documentation supports transparency, accountability, and recordkeeping and is closely associated with Current Good Tissue Practice (cGTP).

For a structured overview showing how traceability fits within the complete regulatory review process, see the HCT/P Regulatory Evaluation Pathway .

Documentation and Regulatory Education

Not sure how these requirements apply to your current sourcing or protocols?

Licensed medical professionals and organizations may request educational materials related to tissue traceability, documentation practices, chain-of-custody standards, and regulatory safeguards referenced within this resource.

Credential verification may be required prior to documentation access.

Request Regulatory Information

Provider Credential Verification Portal

Schedule a Professional Consultation

Infographic illustrating tissue chain-of-custody documentation and traceability stages for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) under 21 CFR Part 1271, including donor recovery, processing, storage, distribution, and final documentation.

Educational diagram illustrating the chain-of-custody traceability pathway for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) under the regulatory framework described in 21 CFR Part 1271.

Purpose of Chain-of-Custody Documentation

Chain-of-custody documentation establishes a traceable record of how human tissue materials move through each stage of recovery, processing, storage, distribution, and final disposition. These records help maintain accountability while supporting compliance with applicable regulatory requirements.

Traceability systems assist tissue establishments and healthcare organizations in documenting the identity, handling, and movement of HCT/Ps throughout the supply chain.

Stages in the Tissue Traceability Process

A complete chain-of-custody record may include documentation associated with multiple stages of tissue handling, including:

Donor recovery and tissue procurement
Transportation to processing facilities
Tissue processing and preparation
Storage and inventory management
Distribution and shipment documentation
Documentation associated with final clinical disposition

Maintaining documentation across each stage helps preserve traceability throughout the lifecycle of an HCT/P and supports quality system recordkeeping.

Relationship to Current Good Tissue Practice (cGTP)

Current Good Tissue Practice (cGTP) requirements under 21 CFR Part 1271 Subpart D include recordkeeping and documentation practices intended to support traceability and accountability throughout the handling of Human Cells, Tissues, and Cellular and Tissue-Based Products.

These safeguards include documentation related to recovery, processing, storage, labeling, packaging, distribution, and record retention.

Importance of Traceability in Regulatory Oversight

Traceability systems support regulatory oversight by allowing tissue establishments and healthcare organizations to document how HCT/Ps were recovered, processed, stored, distributed, and managed throughout the supply chain.

Chain-of-custody documentation may also assist supplier evaluation, quality assurance activities, and regulatory documentation review when assessing compliance with 21 CFR Part 1271.